Amylyx Pharmaceuticals (NASDAQ:AMLX) Raised to "Buy" at The Goldman Sachs Group

The Goldman Sachs Group upgraded shares of Amylyx Pharmaceuticals (NASDAQ:AMLX - Free Report) to a buy rating in a report issued on Thursday, Marketbeat Ratings reports. The Goldman Sachs Group currently has $10.00 target price on the stock.

AMLX has been the subject of several other research reports. UBS Group raised shares of Amylyx Pharmaceuticals to a "hold" rating in a research report on Tuesday, June 24th. Citigroup initiated coverage on shares of Amylyx Pharmaceuticals in a research note on Tuesday, June 17th. They issued a "buy" rating and a $12.00 price target for the company. TD Cowen initiated coverage on shares of Amylyx Pharmaceuticals in a research note on Friday, May 30th. They issued a "buy" rating for the company. Wall Street Zen lowered shares of Amylyx Pharmaceuticals from a "hold" rating to a "sell" rating in a research note on Saturday, June 14th. Finally, Guggenheim initiated coverage on shares of Amylyx Pharmaceuticals in a research note on Tuesday, June 24th. They issued a "buy" rating and a $17.00 price target for the company. One research analyst has rated the stock with a sell rating, two have given a hold rating, nine have assigned a buy rating and two have issued a strong buy rating to the company's stock. According to data from MarketBeat.com, Amylyx Pharmaceuticals currently has an average rating of "Moderate Buy" and an average target price of $11.75.

Amylyx Pharmaceuticals Price Performance

NASDAQ AMLX traded up $0.27 during mid-day trading on Thursday, hitting $7.66. The company's stock had a trading volume of 1,022,188 shares, compared to its average volume of 1,175,061. Amylyx Pharmaceuticals has a 52-week low of $1.76 and a 52-week high of $7.72. The stock's fifty day simple moving average is $5.48 and its two-hundred day simple moving average is $4.34. The firm has a market capitalization of $682.37 million, a P/E ratio of -2.47 and a beta of -0.49.

Amylyx Pharmaceuticals (NASDAQ:AMLX - Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The company reported ($0.42) EPS for the quarter, beating the consensus estimate of ($0.45) by $0.03. On average, equities analysts forecast that Amylyx Pharmaceuticals will post -2.2 earnings per share for the current fiscal year.

Institutional Trading of Amylyx Pharmaceuticals

Several institutional investors have recently added to or reduced their stakes in AMLX. Valeo Financial Advisors LLC bought a new stake in Amylyx Pharmaceuticals during the first quarter valued at $35,000. Alpine Global Management LLC bought a new position in shares of Amylyx Pharmaceuticals during the fourth quarter worth about $45,000. Fox Run Management L.L.C. bought a new position in shares of Amylyx Pharmaceuticals during the fourth quarter worth about $45,000. R Squared Ltd grew its position in shares of Amylyx Pharmaceuticals by 99.9% during the first quarter. R Squared Ltd now owns 12,736 shares of the company's stock worth $45,000 after acquiring an additional 6,366 shares during the last quarter. Finally, RPO LLC bought a new position in shares of Amylyx Pharmaceuticals during the fourth quarter worth about $46,000. Institutional investors own 95.84% of the company's stock.

About Amylyx Pharmaceuticals

Amylyx Pharmaceuticals, Inc, a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada.